KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Payables (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Payables for 16 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • Quarterly Payables rose 103.91% to $20.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Dec 2025, up 103.91% year-over-year, with the annual reading at $20.9 million for FY2025, 103.91% up from the prior year.
  • Payables for Q4 2025 was $20.9 million at Halozyme Therapeutics, up from $15.4 million in the prior quarter.
  • The five-year high for Payables was $20.9 million in Q4 2025, with the low at $535000.0 in Q1 2021.
  • Average Payables over 5 years is $11.8 million, with a median of $12.3 million recorded in 2022.
  • The sharpest move saw Payables tumbled 93.57% in 2021, then surged 1048.15% in 2022.
  • Over 5 years, Payables stood at $1.5 million in 2021, then soared by 1048.15% to $17.7 million in 2022, then crashed by 33.22% to $11.8 million in 2023, then fell by 13.26% to $10.2 million in 2024, then soared by 103.91% to $20.9 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $20.9 million, $15.4 million, and $18.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.